Core Viewpoint - The article discusses the recent updates to the National Medical Insurance and Commercial Health Insurance drug directories, highlighting the successful negotiations and the inclusion of innovative drugs, which aim to enhance the healthcare system in China [4][5]. Group 1: Drug Directory Updates - The total number of drugs in the basic medical insurance directory increased from 3,159 to 3,253, with 1,857 Western medicines and 1,396 traditional Chinese medicines included [5]. - A total of 127 drugs outside the directory participated in negotiations, with 112 successfully negotiated, achieving a success rate of 88%, the highest in seven years [5]. - The newly added drugs primarily target cancer, infections, chronic diseases, and rare diseases, indicating a focus on critical therapeutic areas [5]. Group 2: Commercial Health Insurance Directory - The first version of the commercial health insurance directory included 24 drugs for price negotiations, with 19 successfully included, resulting in a success rate of 79% [5]. - Among the included drugs, 9 are classified as first-class new drugs, addressing significant clinical needs such as Alzheimer's disease and multiple myeloma [5]. - The directory aims to bridge the gap between basic medical insurance and commercial health insurance, focusing on high-value drugs not covered by basic insurance [8]. Group 3: Negotiation and Renewal Rates - The recent adjustments added 114 new drugs while removing 29 drugs that were either replaced or not in production, with 111 being newly listed within five years [6]. - The renewal rate for drugs already in the directory reached 75%, indicating strong support for existing treatments [6]. - The overall approval rate for drugs undergoing formal review was 41.48%, reflecting a stringent evaluation process [6]. Group 4: Policy Support for Innovation - The dual-directory system is designed to support "true innovation" and "differentiated innovation" in the pharmaceutical sector [7]. - Measures introduced in June 2025 aim to enhance support for innovative drug development and encourage their inclusion in both insurance directories [7][8]. - The commercial health insurance directory complements the basic insurance directory by focusing on high-value drugs with significant clinical benefits [8].

Group 1 - The domestic equity market indices generally rose, with the ChiNext Index increasing by 1.86%. Cycle-themed funds outperformed, while consumer and pharmaceutical-themed funds experienced net value adjustments. A total of 39 new funds were established, with a combined issuance of 36.589 billion units. Stock ETFs saw a slight inflow of funds, primarily increasing positions in mid-cap and TMT-themed ETFs, while Hong Kong stock ETFs experienced significant inflows. The active equity fund positions showed a downward trend [5]. - The price of praseodymium and neodymium oxide has risen for a consecutive month, and the price of electrolytic cobalt has also increased for a month. The lithium price has reached approximately 92,000 yuan per ton, and it is recommended to focus on companies with cost advantages and resource expansion in the lithium mining sector. Prices for various cobalt products have risen, and tungsten prices remain at a high level not seen since 2012. The price of praseodymium and neodymium oxide is at a 19-month high [5]. - The new version of the medical insurance directory and the first version of the commercial insurance innovative drug directory were released simultaneously. The success rate of negotiations for the basic medical insurance reached 88%, the highest in seven years, while the first commercial insurance directory included 19 drugs with a negotiation success rate of 79%. The expansion and quality improvement of the medical insurance directory are emphasized, with a pass rate of 41.48% for drugs outside the directory undergoing expert review, indicating a strict overall standard. The renewal rate for negotiated drugs within the directory is as high as 75% [5]. Group 2 - The investment value analysis of Laopu Gold highlights its successful penetration into the market through product design that incorporates classic cultural elements from both Eastern and Western traditions, appealing to younger consumers. The brand's positioning in high-end shopping districts enhances its luxurious image, and despite a limited number of stores, the output per store is significant. The online strategy accelerates the penetration of traditional gold products, attracting young customers with lower-priced items, which also supports long-term offline development [7]. - For Anjui Foods, the company continues to show positive operational trends in the fourth quarter. Although the intensity of price competition in the industry remains to be observed, feedback from distributors and market responses indicate a potential easing of price competition among frozen food companies since the third quarter, which may lead to improved profitability [7].

本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 能源央企巨头，资产规模与效益同步增长 中国石油天然气集团有限公司是国有重要骨干企业和全球主要的油气生产商和供应商之一，是集国内外油气勘 探开发和新能源、炼化销售和新材料、支持和服务、资本和金融等业务于一体的综合性国际能源公司。公司是 国有独资企业，旗下包含中国石油天然气股份有限公司、油气新能源板块、炼化新材料板块、支持服务板块、 资本金融板块五大部分，旗下直接拥有中国石油天然气股份有限公司、中油工程、中油资本三家上市公司，中 国石油天然气股份有限公司控股昆仑能源、大庆华科两家上市公司。2021年以来，公司把握全球能源新周期， 高质量发展迈上新台阶，各项工作成效显著，实现了资产规模与经营效益同步增长。2024年，中国石油集团公 司实现营业总收入31362亿元，同比-0. ...

报告摘要 本周小结：矿端短缺+美国以外地区低库存，看好铜价继续上行 截至2025年12月5日，SHFE铜收盘价92780 元/吨，环比11月28日+6.12%；LME铜收盘价11665 美元/吨， 环比11月28日+4.38%。12月3日LME注销仓单库存达5.7万吨（占LME总库存35%），引发市场对于美国以 外地区低库存的担忧；嘉能可当日将2026年铜产量指引中枢下调9万吨，显示铜矿扰动增强；线缆企业开 工率在铜价维持高位背景下连续回升5周，Q4电网旺季效应仍存；2025Q4空调排产同比下降，但环比改 善；供需仍将维持偏紧格局，继续看好铜价上行。 库存：国内铜社库环比-8.4%，LME铜库存环比+2% （1）港口铜精矿库存：截至2025年12月5日，国内主流港口铜精矿库存75.0 万吨，环比上周+3.7%。 （2）全球电解铜库存：截至2025年12月1日，全球三大交易所库存合计67.6 万吨，环比11月24日+1.0%。 截至2025年12月4日，LME铜全球库存16.3 万吨，环比+2.0%；SMM铜社会库存15.9 万吨，环比11月27 日-8.4%。 供给：10月中国铜矿产量环比-8%、同比-12% ...

Group 1 - The overall A-share market experienced wide fluctuations, with major indices showing slight weekly gains and increased trading volume [5] - The short-term pullback pressure may have been released, indicating a return to a consolidation phase, with a positive outlook for market rebounds [5] - The investment strategy suggested focuses on "dividend + technology" as the main allocation theme, with dividends expected to perform better in terms of volatility [5] Group 2 - The electrolytic aluminum spot price reached its highest level since May 2022, indicating potential recovery in the steel sector's profitability [6] - The copper industry reported a 1% month-on-month increase in China's electrolytic copper production for November, with cable enterprise operating rates rising for five consecutive weeks [6] - The supply-demand dynamics in the copper market are expected to remain tight, supporting a bullish outlook for copper prices [6] Group 3 - China National Petroleum Corporation is recognized as a significant state-owned enterprise and a major global oil and gas producer, benefiting from its integrated operations across various energy sectors [7] - The energy sector is seeing a focus on investment opportunities in hydrogen, ammonia, and energy storage, with expectations for stable domestic bidding levels in 2026 [7] - The lithium battery sector is highlighted for potential investment opportunities, particularly in lithium mines and production processes that are currently under pressure [7] Group 4 - The first commercial insurance innovative drug directory was released, including 24 drugs, with 19 successfully negotiated for pricing, expanding market opportunities for innovative drugs in China [8] - The implementation of this directory is expected to create a broader market space for innovative pharmaceuticals amid the continuous emergence of new global drugs [8]

Market Overview - The A-share pharmaceutical and biotechnology index fell by 1.17%, underperforming the CSI 300 index by 2.44 percentage points and the ChiNext index by 1.89 percentage points, ranking 17th among 31 sub-industries [4] - The H-share Hang Seng Healthcare Index also declined by 0.71%, lagging behind the Hang Seng Index by 1.45 percentage points [4] R&D Progress - Recent IND applications include Yifang Biotech's D-0502 tablets and Hengrui Medicine's HRS-6257 tablets; clinical applications include BeiGene's BG-C137 injection and Hengrui's HRS-4642 [5] - Shijiazhuang Pharmaceutical's SYS6002 and Zai Lab's Epcoritamab are in Phase III clinical trials; Maiwei Biotech's 9MW3811 is in Phase II; and 3SBio's SSGJ-709 is in Phase I [5] Policy and Market Developments - On December 7, the National Healthcare Security Administration released the new National Basic Medical Insurance Drug Directory and the Commercial Health Insurance Innovative Drug Directory for 2025, with 127 products participating in negotiations, of which 114 were successfully included, achieving a success rate of 88%, the highest in seven years [6] - The first commercial insurance directory included 24 drugs, with 19 successfully negotiated, including CAR-T therapies and treatments for rare diseases such as neuroblastoma and Gaucher disease, as well as Alzheimer's disease [6] - The implementation of the commercial insurance innovative drug directory is expected to open broader market opportunities for innovative drugs in the context of a growing number of "global new" drugs emerging in China [6] Investment Strategy - The investment strategy for the pharmaceutical sector is shifting towards emphasizing the clinical value of drugs, addressing clinical needs of patients, influenced by domestic healthcare policies and global expansion [7] - The focus is on the innovative drug supply chain and innovative medical devices, reflecting a clinical value-based investment approach [7]

Liquidity - The BCI small and medium enterprise financing environment index for November is 52.50, with a month-on-month increase of 0.17% [4] - The M1 and M2 growth rate difference in October is -2.0 percentage points, with a month-on-month increase of 0.8 percentage points [4] - The current price of London gold is $4,197 per ounce [4] Infrastructure and Real Estate Chain - Total inventory of five major steel varieties is at the highest level for the same period in four years [5] - Price changes this week include rebar +0.31%, cement price index -0.10%, rubber -1.01%, coke -3.18%, coking coal -1.41%, iron ore -0.13% [5] - National blast furnace capacity utilization rate, cement, and asphalt operating rates have changed by -0.90 percentage points, -0.30 percentage points, and +0.3 percentage points respectively [5] Real Estate Completion Chain - Prices of titanium dioxide and flat glass have increased by 0.78% and remained unchanged respectively, with glass gross profit at -58 yuan/ton and titanium dioxide gross profit at -1,649 yuan/ton [6] - The operating rate for flat glass this week is 73.63% [6] Industrial Products Chain - Major commodity price performance this week includes cold-rolled steel and copper prices unchanged, aluminum +3.36%, with corresponding gross profit changes turning from loss to profit and increasing by 2.20% and 12.47% respectively [7] - The national semi-steel tire operating rate is 70.92%, with a month-on-month increase of 1.73 percentage points [7] Subcategories - Electrolytic aluminum spot price reaches the highest level since May 2022, while tungsten concentrate price continues to reach the highest level since 2012 [8] - The price of graphite electrodes is 19,000 yuan/ton, with a month-on-month increase of 2.70%, and the comprehensive gross profit is 1,357.4 yuan/ton, down 17.59% [8] - The price of electrolytic aluminum is 22,150 yuan/ton, with a month-on-month increase of 3.36%, and estimated profit is 4,750 yuan/ton (excluding tax), up 12.47% [8] - The price of electrolytic copper is 91,600 yuan/ton, with a month-on-month increase of 4.71% [8] - The price of tungsten concentrate is 354,000 yuan/ton, with a month-on-month increase of 4.42% [8] Price Comparison Relationships - The price ratio of rebar and iron ore this week is 4.09 [10] - The price difference between hot-rolled and rebar steel is 40 yuan/ton [10] - The price difference between Shanghai cold-rolled and hot-rolled steel is 530 yuan/ton, with a month-on-month increase of 40 yuan/ton [10] - The price ratio of stainless steel hot-rolled to electrolytic nickel is 0.11 [10] - The price difference between small rebar (mainly used in real estate) and large rebar (mainly used in infrastructure) is 170 yuan/ton, with a month-on-month increase of 6.25% [10] - The price difference between medium-thick plates and rebar is 70 yuan/ton [10] - The London spot gold-silver price ratio is 73 times this week [10] Export Chain - The new export orders PMI for China in November is 47.60%, with a month-on-month increase of 1.7 percentage points [11] - The China Containerized Freight Index (CCFI) comprehensive index this week is 1,114.89 points, with a month-on-month decrease of 0.62% [11] - The U.S. crude steel capacity utilization rate this week is 75.80%, with a month-on-month decrease of 1.10 percentage points [11] Valuation Percentiles - The CSI 300 index increased by 1.28% this week, with the best-performing cyclical sector being industrial metals (+9.14%) [12] - The PB ratio of ordinary steel and industrial metals relative to the CSI 300 PB ratio is 37.97% and 100.00% respectively [12] - The current PB ratio of the ordinary steel sector relative to the CSI 300 PB ratio is 0.53, with the highest value since 2013 being 0.82 (reached in August 2017) [12]

Group 1: Energy Storage - In November, domestic energy storage completed a total of 10GW/29.7GWh in bidding, with independent storage projects accounting for 90% of the total. The average bid price for 2/4h systems was 0.594/0.494 CNY/Wh, showing a slight decrease compared to October. It is expected that independent storage bidding will maintain a good level in 2026, supported by the development of the industry and a complete revenue model through energy, capacity, and ancillary service markets [4] - The logic for overseas energy storage continues to evolve, with the overall electricity shortage in the U.S. remaining unchanged. Future technological advancements are expected to be a key focus, with attention on overseas storage and SST opportunities. Demand for energy storage in non-U.S. countries is also anticipated to rise, such as in Middle Eastern data centers and Ukraine's reconstruction efforts [4] Group 2: Hydrogen and Ammonia - The Jilin Provincial Ecological Environment Department has accepted the environmental impact report for a project by Liao Yuan Tian Yi Hydrogen Energy Technology Co., Ltd., which aims to produce 180,000 tons of green methane annually. This project is part of the "wind-solar-storage-hydrogen-ammonia integration" series under a government framework agreement. The hydrogen and ammonia sector is expected to gain more investment due to dual benefits from China's future industries and the EU's carbon tariff in 2026 [5] Group 3: Lithium Battery - Production in December is expected to remain stable, with demand anticipated to improve in January. The market is currently negotiating on the demand side regarding domestic energy storage bidding expectations for 2026, while also monitoring the sales of new energy vehicles. On the supply side, the lithium battery industry is experiencing a "reverse involution" logic, establishing a trend of supply-demand improvement. Short-term expectations for lithium hexafluorophosphate are already high, and various segments are gradually entering long-term contract signing phases. Mid-term investment opportunities should focus on lithium mines with significant supply variability and membrane segments where profitability does not support expansion [6]

点击注册小程序 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 本周市场核心观点： 本周（2025.12.01-2025.12.05，下同）A股整体宽幅震荡，主要宽基指数周度小幅收涨。量能表现方面， 主要宽基指数量能均回升。资金面方面，本周股票型ETF小幅净流入，中小盘主题ETF为净流入主力；融 资增加额维持正值，环比上周略有下降。 从本周市场表现来看，短线回调压力或已释放，市场再度进入震荡区间。资金面较市场交易量能更为积 极，反弹或将延续。建议以"红利+科技"作为配置主线，红利或在波动方面占优。 本周市场各指数全线上涨，上证综指上涨0.37%，上证50上涨1.09%，沪深300上涨1.28%，中证500上涨 0.94%，中证1000上涨0.11%，创业板指上涨1.86%，北证50指数上涨 ...

点击注册小程序 本周数据更新：本周动力煤价格加速下跌 查看完整报告 特别申明： 本订阅号中所涉及的证券研究信息由光大证券研究所编写，仅面向光大证券专业投资者客户，用作新媒体形势下研究 信息和研究观点的沟通交流。非光大证券专业投资者客户，请勿订阅、接收或使用本订阅号中的任何信息。本订阅号 难以设置访问权限，若给您造成不便，敬请谅解。光大证券研究所不会因关注、收到或阅读本订阅号推送内容而视相 关人员为光大证券的客户。 报告摘要 本周行情回顾： 本周SW公用事业一级板块上涨0.12%，在31个SW一级板块中排名第17；沪深300上涨1.28%，上证综指上 涨0.37%，深证成指上涨1.26%，创业板指上涨1.86%。细分子板块中，火电下跌0.2%，水电上涨0.66%， 光伏发电上涨0.07%，风力发电上涨0.62%，电能综合服务上涨0.35%，燃气下跌1.66%。本周公用事业涨 幅前五的个股分别为闽东电力（+16.86%）、中闽能源（+12.62%）、惠天热电（+12.60%）、华通热力 （+7.56%）、德龙汇能（+6.19%）；周跌幅前五的个股分别为上海电力（-13.53%）、恒盛能源 （-12.13%）、大众 ...